Secarna Pharmaceuticals GmbH & Co. KG

BRIEF

published on 05/23/2025 at 09:05, 9 months 28 days ago

Secarna Pharmaceuticals Unveils Promising SECN-15 Data at ASCO 2025

Cancer Therapy Clinical Trial Secarna Pharmaceuticals Antisense Oligonucleotide SECN-15
PRESS RELEASE

published on 05/23/2025 at 09:00, 9 months 28 days ago

Secarna Pharmaceuticals to present new data and clinical strategy for lead antisense oligonucleotide program SECN-15 at ASCO 2025
Secarna Pharmaceuticals to present new data and clinical strategy for SECN-15 at ASCO 2025. Targeting NRP1 with antisense oligonucleotides for solid cancers. Promising therapeutic approach

Secarna Pharmaceuticals Antisense Oligonucleotides SECN-15 ASCO 2025 Clinical Strategy
BRIEF

published on 05/12/2025 at 14:05, 10 months 8 days ago

Secarna Pharmaceuticals and Curie.Bio Sign Research Agreement

Drug Discovery Biopharmaceutical Collaboration Oligonucleotide Therapeutics Research Agreement AI-empowered Platform
PRESS RELEASE

published on 05/12/2025 at 14:00, 10 months 8 days ago

Secarna Pharmaceuticals and Curie.Bio Portfolio Company Enter into Research and Option Agreement
Secarna Pharmaceuticals and Curie.Bio Portfolio Company signed a research and option agreement to accelerate the discovery of novel oligonucleotide therapies

Research Option Agreement Secarna Pharmaceuticals Curie.Bio Oligonucleotide Therapies
BRIEF

published on 04/28/2025 at 14:35, 10 months 22 days ago

Prof. Dr. Vignali Joins Secarna Pharmaceuticals' Scientific Board

Scientific Advisory Board Immuno-oncology Secarna Pharmaceuticals SECN-15 Prof. Dr. Vignali
PRESS RELEASE

published on 04/28/2025 at 14:30, 10 months 22 days ago

Secarna Pharmaceuticals adds leading expert to Scientific Advisory Board with appointment of Prof. Dr. Vignali
Secarna Pharmaceuticals appoints Prof. Dr. Dario Vignali to Scientific Advisory Board, enhancing expertise in oncology research and immunotherapy strategies for solid tumors

Scientific Advisory Board Immunotherapy Oncology Research Secarna Pharmaceuticals Prof. Dr. Dario Vignali
BRIEF

published on 03/26/2025 at 14:05, 11 months 25 days ago

Secarna Pharmaceuticals Highlights Promising Data on SECN-15 at AACR

Cancer Therapy Checkpoint Inhibitors SECN-15 Tumor Microenvironment NRP1 Targeting
PRESS RELEASE

published on 03/26/2025 at 14:00, 11 months 25 days ago

Secarna Pharmaceuticals to present positive new data on antisense oligonucleotide SECN-15 targeting NRP1 as monotherapy and in combination with immune checkpoint inhibitors at AACR
Secarna Pharmaceuticals to present positive new data on antisense oligonucleotide SECN-15 targeting NRP1 at AACR, showcasing potential to enhance immune checkpoint inhibitors' efficacy

Secarna Pharmaceuticals AACR Antisense Oligonucleotide SECN-15 NRP1
BRIEF

published on 10/31/2024 at 16:08, 1 year 4 months ago

Secarna Pharmaceuticals Appoints New CEO Konstantin Petropoulos

CEO Appointment Biopharmaceuticals Secarna Pharmaceuticals Konstantin Petropoulos Oligonucleotide Therapeutics
PRESS RELEASE

published on 10/31/2024 at 16:03, 1 year 4 months ago

Secarna Announces Appointment of Konstantin Petropoulos as Chief Executive Office
Secarna Pharmaceuticals announces Konstantin Petropoulos as new CEO, succeeding Alexander Gebauer, focusing on oligonucleotide therapeutics. Petropoulos brings extensive industry experience

Business Development CEO Appointment Secarna Pharmaceuticals Konstantin Petropoulos Oligonucleotide Therapeutics

Published on 03/20/2026 at 23:00, 3 hours 43 minutes ago

Cypher Announces Private Placement
Published on 03/20/2026 at 21:30, 5 hours 13 minutes ago

Sky Gold Sets Options
Published on 03/20/2026 at 21:15, 5 hours 28 minutes ago

Earthwise Minerals Announces Private Placement
Published on 03/20/2026 at 13:30, 13 hours 13 minutes ago

Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 14 hours 13 minutes ago

CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals

View all ACCESSWIRE

Published on 03/20/2026 at 22:45, 3 hours 58 minutes ago

Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 5 hours 38 minutes ago

Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 5 hours 38 minutes ago

Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 21:00, 5 hours 43 minutes ago

BRP Unveils the Winners of its 6th International Design Challenge
Published on 03/20/2026 at 20:05, 6 hours 38 minutes ago

INVESTOR ALERT: Goeasy Ltd. Shareholder Class Action

View all EQS

Published on 03/20/2026 at 19:00, 7 hours 43 minutes ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 18:15, 8 hours 28 minutes ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 17:45, 8 hours 58 minutes ago

Cie du Bois Sauvage : Annual report 2025
Published on 03/20/2026 at 16:57, 9 hours 46 minutes ago

Number of shares and voting rights - February 2026 (In French only)
Published on 03/19/2026 at 18:00, 1 day 8 hours ago

Filing of the 2025 Universal Registration Document

View all LES ECHOS COMFI WIRE

News